



Published in final edited form as:

Annu Rev Biochem. 2009 ; 78: 177–204. doi:10.1146/annurev.biochem.78.082907.145410.

Getting a grip on prions: oligomers, amyloids and pathological membrane interactions

Byron Caughey, Gerald S. Baron, Bruce Chesebro, and Martin Jeffrey

Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA, and Veterinary Laboratories Agency (Lasswade), Pentlands Science Park, Bush Loan, Penicuik, Midlothian, EH26 0PZ, UK

Abstract

The prion (infectious protein) concept has evolved with the discovery of new self-propagating protein states in organisms as diverse as mammals and fungi. The infectious agent of the mammalian transmissible spongiform encephalopathies (TSE) has long been considered to be the prototypical prion, and recent cell-free propagation and biophysical analyses of TSE infectivity have now firmly established its prion credentials. Other disease-associated protein aggregates, such as some amyloids, can also have prion-like characteristics under certain experimental conditions. However, most amyloids appear to lack the natural transmissibility of TSE prions. One feature that distinguishes the latter from the former is the glycoposphatidylinositol membrane anchor on prion protein, the molecule that is corrupted in TSE diseases. The presence of this anchor profoundly affects TSE pathogenesis, which involves major membrane distortions in the brain, and may be a key reason for the greater neurovirulence of TSE prions relative to many other autocatalytic protein aggregates.

Keywords

protein misfolding diseases; glycoposphatidylinositol anchor; exosomes; tunneling nanotubes; membranes

INTRODUCTION

In the 1960s, the notion that corrupted host proteins could act as infectious pathogens was proposed by JS Griffith as an explanation for the mysterious sheep disease called scrapie (1). In 1982, Stanley Prusiner coined the term prion for such proteinaceous infectious agents that apparently lack their own specific nucleic acid genome (2). Shortly thereafter, Prusiner discovered a host protein, prion protein (PrP), whose alteration is critical in the pathogenesis of the transmissible spongiform encephalopathies (TSEs) of mammals. However, it was exceptionally difficult to show unequivocally that prions are composed solely of modified PrP without any prion-specific nucleic acid. Thus, for a long time it remained uncertain whether prions exist as infectious pathogenic proteins in mammals. Only recently has there been a report of the propagation of robust mammalian prions *in vitro* using semi-purified molecular constituents. This directly implicates PrP conformational change in prion propagation and seems to rule out the need for an agent-specific protein-encoding nucleic acid (3,4). Meanwhile, in 1994, Reed Wickner argued compellingly that mysterious epigenetic elements of yeast could also be explained by the transfer of aggregated proteins from one cell to another (5). In doing so, Wickner proposed that the prion concept be extended to include these proteinaceous entities that could act as infectious agents and/or convey heritable changes in phenotype without mediation by nucleic acids. Many diverse biological phenomena have now been described as being prions or prion-like. There are several basic requirements for a prion (6). First, there

must be a self-propagating state of a protein (the prion) that is biologically accessible but rarely formed spontaneously. Second, prions must replicate themselves by acting on their non-prion substrate protein. And third, prions must spread to naive hosts and find new substrate pools for replication. Typically, prions also cause phenotypic changes in the host.

In this review, we will first describe the challenging hunt for molecularly defined mammalian TSE prions. We will then consider recent insights into their three-dimensional structure, biogenesis, and neuropathogenic effects. Emphasis will be given to a unique aspect of mammalian TSE diseases, that is, the anchoring of the protein of interest (PrP) to membranes by a glycosylphosphatidylinositol (GPI) moiety. This feature strongly influences TSE prion pathogenicity. Moreover, neuronal membrane abnormalities figure prominently in the pathognomonic lesions of TSE diseases, prompting us to also consider the extent to which membrane tethering plays a role in distinguishing TSE prion biology from the biology of other types of prions or prion-like phenomena in mammals. A number of different proteins of mammals and fungi can be found in altered states with at least some properties of prions. These examples extend the prion concept and help to define its fundamental features and useful limits.

IN VITRO PROPAGATION OF PRIONS

PrP conversion

The most compelling way to demonstrate the composition of prions is to propagate them in vitro using defined biochemical constituents. Mammalian prion propagation is usually associated with the post-translational conversion of the host's normal, soluble, protease-sensitive PrP (PrP^C or PrP^{sen}) to a less soluble and more proteinase-K resistant state (PrP^{RES} or PrP^{Sc}) (7). Initial attempts to propagate prions in extensively purified cell-free systems showed that PrP^{RES} can cause PrP^C to convert to a PrP^{RES}-like protease-resistant state in a highly species- and sequence-dependent manner consistent with known prion transmission barriers in vivo (8–11). PrP^{RES} with PrP^C converting activity is oligomeric, and, newly converted PrP molecules become associated with PrP^{RES} oligomers (12–14). These and other features of the conversion reaction are consistent with either non-catalytic or autocatalytic (templated) seeded polymerization mechanisms initially outlined by Carleton Gadjusek and Peter Lansbury (Figure 1) (12,15,16). PrP^{RES} oligomers of different prion strain-associated conformations are capable of imposing those distinct conformations on PrP^C molecules during conversion (8). This provides a potential molecular basis for the propagation of prion strains without the need for a prion-specific nucleic acid. Although the presence of cell-free PrP^C converting activity correlates with the presence of prion infectivity (17), the yields of the initial cell-free PrP^C conversion reactions were usually substoichiometric relative to the PrP^{RES} seed, and the generation of prion infectivity was not demonstrable (18).

Synthetic prions

More recently, synthetic amyloid fibrils composed of a truncated fragment of recombinant PrP^C (PrP residues 90–231) were shown to accelerate clinical disease when inoculated into transgenic mice that overexpress PrP⁹⁰⁻²³¹ by ~16-fold (19,20). Furthermore, brain tissue from these sick mice contained prions that caused TSE disease when inoculated into wild-type mice. These striking results suggested that amyloid preparations of recombinant PrP alone instigated transmissible prion disease, albeit in an unnatural host that, by virtue of PrP overexpression, was likely to be strongly primed for PrP aggregation and susceptibility to both induced and spontaneous prion disease. Importantly, the initial synthetic fibrils had no activity in wild-type mice, implying that these “synthetic prions” were many orders of magnitude less infectious than *bona fide* scrapie prions. There are several possible explanations for these results: 1) recombinant PrP⁹⁰⁻²³¹ amyloid may be infectious, but with extremely poor efficiency; 2) the infectious entity might not be the amyloid itself, but a different form of PrP-

containing particle that is present at only trace quantities in the synthetic amyloid preparation; 3) robust recombinant PrP prions might require another molecular constituent [*e.g.* polyanions such as glycosaminoglycans (GAGs) or RNA (4)]; or 4) the amyloid preparations might not be infectious at all but may accelerate a neurodegenerative process that occurs spontaneously in transgenic mice overexpressing truncated PrP⁹⁰⁻²³¹. In this latter case, the infectivity for wild-type mice could have arisen spontaneously in the transgenic mice, as has been reported in other transgenic mice that overexpress PrP mutants (21). Further studies will be required to discriminate between these possibilities.

PMCA

In a major breakthrough, brain-homogenate-based reactions were developed that allowed unlimited amplification of both PrP^{RES} and robust prions that were infectious for wild-type rodents (3,22,23). This amplification protocol, called PMCA for protein misfolding cyclic amplification, involves introducing minute amounts of an infectious PrP^{RES}-containing seed into a homogenate of brain from an uninfected animal which provides PrP^C and any cofactors that might be needed. The suspension is subjected to cycles of incubation, which allows for seeded polymerization of the PrP^C, and sonication, which fragments the polymers to generate more seeds (Figure 2). Two striking features of the PMCA reaction is its sensitivity and amplification power (24). As little as ~1 attogram (10^{-18} g) or the equivalent of ~20 PrP^{RES} molecules can be detected by this method, providing the basis for extraordinarily sensitive prion assays and potentially, diagnostic tests for prion diseases.

Prion amplification has been reported in either prion-seeded or spontaneous conversion reactions containing largely purified, brain-derived PrP^C and synthetic polyA RNA (Figure 2) (4). Lipids and perhaps other molecules copurify with the PrP^C in these preparations and therefore might also be important in prion formation. This seminal report not only provided long-awaited direct support for the PrP-based prion hypothesis, but suggested that other non-protein molecules, such as RNA molecules, are critical either as prion components or accessories in the PrP conformational conversion (25). The spontaneous instigation of prion formation in these experiments may represent an *in vitro* equivalent of sporadic Creutzfeldt-Jakob disease, which, for epidemiological reasons, is widely assumed to be an example of spontaneous prion disease in humans.

Recombinant PrP-PMCA and related amplification reactions

In attempts to further refine the understanding of prion composition, PMCA-like amplification reactions (rPrP-PMCA and QuIC) have been performed using purified bacterially expressed recombinant PrP^C as a substitute for brain-derived PrP^C (26,27). PrP^{RES}-seeded rPrP-PMCA and QuIC reactions produce a protease-resistant, largely beta-sheet, fibrillar PrP recombinant conversion product that serves as a highly amplified marker of sub-femtogram amounts of PrP^{RES}. Furthermore, these and related reactions can be much faster than conventional PMCA reactions, improving prospects for the development of practical prion assays and diagnostic tests (26–28). However, inoculations of hamster rPrP-PMCA product into hamsters have not yet revealed clear evidence of prion infectivity (R. Atarashi, G. Raymond and B. Caughey, unpublished data). Thus, like the truncated recombinant PrP amyloid fibrils called “synthetic prions” (19), the infectivity of the rPrP-PMCA product appears to be much lower than either PrP^{RES} itself or the product of PrP^{RES} amplification in PMCA reactions using brain-derived PrP^C, if it proves to be infectious at all. It should be revealing to determine whether the apparently vast difference in infectivity between these various PrP aggregates is a matter of molecular composition, conformation, protease-resistance, ultrastructure, cofactors and/or aggregation conditions. Two notable features of natural PrP^C that are lacking on the recombinant PrP^C are N-linked glycans and the GPI anchor. Interestingly, these post-translational modifications do not appear to be essential for the generation of infectious prions

as indicated by studies of scrapie-infected transgenic mice that express PrP^C molecules lacking these modifications (29–31). These observations suggest that conformational details and/or non-PrP molecular cofactors are more critical determinants of prion infectivity.

STRUCTURAL STUDIES OF PrP OLIGOMERS AND FIBRILS

One of the greatest hurdles in understanding PrP^{RES} is the lack of biophysical techniques suitable for determining the high-resolution structures of non-crystalline fibrillar protein assemblies. The preparations of PrP^{RES} that are of the highest purity have most often contained amyloid-like fibrils which have been characterized in terms of fibril dimensions (32–34) and secondary structure composition (35–38). Visualization of the protein core of wild-type prion fibrils can be obscured by heavy glycosylation and GPI anchors (Figure 3A). However, plaques and fibrils containing mostly unglycosylated and anchorless PrP^{RES} have been isolated from scrapie-infected transgenic mice expressing only anchorless PrP^C (34). These fibrils are composed of protofilaments 3.0–3.5 nm in width as measured by negative stain transmission electron microscopy (Figure 3A). The protofilament widths and twist periodicities can vary significantly with scrapie strain, indicating strain-dependent fibril ultrastructures. This expands the list of strain-dependent features of PrP^{RES} which includes secondary structures (37,38), proteolytic sensitivities (39), glycoform patterns (40–43), stabilities (44) and conformational templating activities (8).

Electron crystallography and modelling

So far, the highest resolution information derived from infectious PrP^{RES} preparations has come from analyses of 2-dimensional crystals that appeared along with fibrils in certain PrP^{RES} preparations (45) (Figure 3B). Image processing and electron crystallography of these structures revealed that they were likely composed of PrP trimers. Based on molecular modelling and mutational analyses, a β -helix model was proposed (46) (Figure 3C). In this model a flexibly disordered domain and helix 1 of PrP^C are coiled into a β -helix, which then aligns with the β -helices of two other PrP^{RES} monomers to form a trimer. N-linked glycans are displayed on the outside of the trimer. An alternative model has been developed on the basis of molecular dynamics simulations and docking procedures (47,48) (Figure 3C). In the resulting spiral model, monomers are joined together via intermolecular β -sheets and can be readily assembled into continuous twisting filaments. Both the β -helix and spiral models are close to being consistent with the protofilament dimensions measured in the anchorless PrP^{RES} fibrils (34); however, the spiral model is more consistent with a variety of other biochemical characteristics of PrP^{RES} (48).

Other probing of fibril structure

Recent studies of synthetic recombinant PrP 90–231 amyloids using hydrogen/deuterium exchange and electron spin resonance provided evidence that residues ~160–220 could form parallel, in-register β -sheet structures that were unlike either the spiral or β -helix models (49, 50) (Figure 3D). In contrast, solid state NMR studies of fibrils of recombinant human PrP residues 23–144, which corresponds to a Gerstmann-Straussler-Scheinker syndrome-associated mutant PrP (Y145stop) in humans, showed that residues 112–144 could form a compact, highly ordered core, while the remainder of the residues toward the N-terminus were largely unordered (51). Earlier studies of disease-inducing fibrils of murine PrP residues 89–143 showed that residues 112–124 formed an extended β -sheet conformation without the β -strands being in a parallel, in-register alignment (52). These and other recent developments in the analysis of a variety of other prion proteins and peptide amyloids (53–64) are laying the foundation for more detailed investigation of the PrP^{RES} structures. Particularly noteworthy are the first high-resolution X-ray diffraction-based structures of amyloid fibrils of short peptides determined by the Eisenberg group (65,66). One important theme that emerges from

these structures is that amyloids can be stabilized by short stretches of amino acid residues that align to form β -sheets which, in turn, are welded to adjacent sheets by the close interdigitation of side chains, forming a dehydrated “steric zipper”.

The most infectious particle

Assessments of the relative infectivity of PrP^{RES} aggregates of various sizes indicated that the most infectious particle per unit protein is ~300–600 kDa, or the mass equivalent of 14–24 PrP monomers, and the smallest oligomer with cell-free PrP^C converting activity is larger than a PrP pentamer in the presence of a low concentration of SDS (13). These studies provide evidence that as long as the infectious particles are above a certain size, presumably related to a stability threshold of some sort, it is the concentration of particles rather than the concentration of PrP^{RES} molecules *per se* that correlates best with infectivity titer. Still, the multimeric nature and heterogeneity of infectious PrP oligomers, as well as uncertainties about the role of other potential molecular constituents, greatly complicates more detailed analyses of their structures by conventional techniques of structural biology.

BIOGENESIS OF PrP^{RES}

One of the difficulties in reconstituting prion propagation with defined molecular constituents may be the recapitulation of the membrane microenvironment that supports PrP^{RES} formation *in vivo*. The PrP^C polypeptide is first synthesized as a nascent GPI-anchored glycoprotein in the endoplasmic reticulum (ER), subjected to glycan modifications in the Golgi apparatus, and then transported to the cell surface (Figure 4) where it is associated primarily with cholesterol-rich raft membrane subdomains. In the case of familial TSE-associated mutant PrP^C molecules, spontaneous folding abnormalities can occur in the endoplasmic reticulum and/or Golgi apparatus [reviewed in (67)]. In scrapie-infected cells, the conversion of mature PrP^C to PrP^{RES} occurs on the cell surface and/or in endosomal vesicles that are internalized from the cell surface (68–70). In contrast to PrP^C, PrP^{RES} is resistant to detergent solubilization, proteinase K, and phosphatidylinositol-specific phospholipase C (which cleaves the GPI anchor). PrP^{RES}, with the apparent assistance of cofactors, directly induces PrP^C conversion via an ill-defined templating or seeding mechanism which results in PrP^C joining the PrP^{RES} oligomer/polymer. These apparent cofactors include sulfated glycosaminoglycan (GAG)-containing proteoglycans (71–73) and laminin receptor and its precursor (LRP/LR) (74). Although the mechanistic role of these accessory molecules is unclear, there is evidence that each can interact directly with PrP molecules and might therefore i) prime PrP^C conformationally for conversion, ii) pre-organize or orient PrP^C and PrP^{RES} molecules for efficient conversion and/or iii) help sequester PrP^C and PrP^{RES} together in the membrane microdomain or subcellular compartment where efficient conversion occurs. Another possible “cofactor” in conversion could be membrane surfaces, which like GAGs, can be polyanionic and induce conformational changes in PrP molecules (see below). The importance of membrane domain structure is indicated by the influence of alterations in raft membrane components such as cholesterol (75), cholesterol esters (76) and sphingolipids (77) on PrP^{RES} formation, but the mechanism of such effects are not clear.

FIBRILLAR VS NONFIBRILLAR PrP^{RES} DEPOSITS: INFLUENCE OF MEMBRANE ASSOCIATION

Once PrP^{RES} is made, it can accumulate on the cell surface, in intracellular vesicles (e.g. lysosomes), or in extracellular deposits such as amyloid plaques (Figure 4). Amyloid plaques are comprised of bundles of fibrillar protein aggregates with a core β -sheet secondary structure that typically gives a cross-beta X-ray diffraction pattern and characteristic staining by Congo red and thioflavins S and T. In most types of TSE diseases in natural hosts expressing GPI-

anchored PrP^C, amyloid plaques are uncommon or absent altogether. More typical PrP^{RES} deposits such as those described at the light microscopy level as granular or diffuse punctate patterns (Figure 5) are usually associated with membranous ultrastructures that lack visible fibrils (78). It is unclear whether these PrP^{RES} deposits are structurally distinct from amyloids or simply amyloid fibrils whose visualization is impaired by their small size, irregular length, or association with membranes and/or other structures. It has been reported that amyloid fibrils of PrP^{RES} (scrapie-associated fibrils or prion rods) that are recovered in purified preparations typically arise only when PrP^{RES} is extracted from membranes with detergent (79). Since the evidence that PrP^{RES} can exist in a stable, biologically relevant monomeric state is tenuous, such a result could be consistent with PrP^{RES} existing as a small oligomer or aggregate in its membrane-bound state and assembling into fibrils upon extraction from membranes. A radiation inactivation target size of ~55 kDa suggests that a dimeric form of PrP^{RES} might be the key infectious unit in liposomes (80). On the other hand, detergent-extracted PrP^{RES} preparations can have regular non-fibrillar two-dimensional arrays of PrP^{RES} trimers (45,46) while size-based fractionations of PrP^{RES} particles in detergents indicate that PrP^C converting activity is associated with oligomers larger than PrP pentamers (13). It is clear that PrP^{RES} can also exist in much larger highly stable ordered aggregates under a wide variety of conditions both *in vitro* and *in vivo*, with amyloid fibrils and plaques being the most obvious examples in brain tissue (Figure 5). Further study will be required to determine the nature of membrane-bound states of PrP^{RES} *in vivo* and whether they include individual PrP^{RES} monomers or small oligomers.

Although rare in many TSE diseases, amyloid plaques are especially prominent in humans with familial Gerstmann-Straussler-Scheinker syndrome (GSS) and kuru, and in scrapie-infected transgenic mice expressing only mutated PrP^C that lacks a GPI-anchor and is secreted from cells (29). In GSS patients, the abnormal PrP plaque amyloid that accumulates (PrP^{GSS}) is composed primarily of truncated internal PrP fragments that lack the GPI anchor. In scrapie-infected anchorless PrP transgenic mice, PrP^{RES} accumulates almost exclusively in prominent extracellular amyloid plaques that assemble around brain blood vessels (Figure 5). These perivascular plaques have close morphologic similarity to the cerebrovascular plaques of Alzheimer's disease, including initial fibrilization within capillary basement membranes. This suggests that both the concentration of PrP^{RES} multimers and extracellular matrix components within the endothelial basement membranes are important for the conversion of diffusible forms of PrP into fibrillar amyloid (71,73,81,82). As plaques are formed in several tissues of the scrapie-infected anchorless PrP transgenic mice the anchorless PrP^C substrate must be capable of being secreted by a number of different cell types and diffusing to the amyloid plaques for conversion at the growing tips of fibrils.

TSE PRION TRANSMISSION, UPTAKE AND TRANSPORT MECHANISMS

TSE prions can be naturally or experimentally transmitted to new individuals via inoculation into several peripheral sites with subsequent and critical spread to the central nervous system (CNS). After oral challenge, infectivity can be taken up by gut mucosa and Peyer's patches and then be transferred somehow to intestinal nerve endings (83–85). However, orally acquired prion diseases do not invariably affect lymphoid tissues or the peripheral nervous system. In such situations haematogenous neuroinvasion, most probably involving specialized capillaries within the circumventricular organs of the brain, is a likely alternative route (86). Haematogenous neuroinvasion can also occur following blood transfusion from infected donors (87). With intra-tongue inoculations, transport to the CNS occurs efficiently via cranial nerves (88). Clearly, the spread of prion infections to and within the CNS requires the transfer of prions within and between cells.

PrP^{RES} uptake and acute induction of PrP^C conversion

A variety of cultured cell types are capable of sustaining prion infections. Neuronal cells can endocytose PrP^{RES} aggregates and transport them (see Supplemental Material link in the online version of this article or at <http://www.annualreviews.org/>) via acidic transport vesicles throughout the cytoplasm and along neuritic projections to points of contact with other cells (Figure 6) (89). Concurrently, new PrP^{RES} formation and chronic scrapie infections can be established (89, 90). The uptake mechanism does not appear to be specific to GPI-anchored PrP^{RES} because similar uptake and vesicular transport can occur with other types of amyloid fibrils such as those composed of Alzheimer's beta peptide or anchorless recombinant PrP. Uptake of exogenous PrP^{RES} can depend upon heparan sulfate-containing proteoglycans [(72, 91), but also consider (92)] and 37/67 kDa laminin receptor (93), but not PrP^C (89, 90, 92). However, cell surface PrP^C expression is obviously required for new PrP^{RES} formation and the maintenance of scrapie infections. Presumably, contacts between incoming PrP^{RES} and the endogenous PrP^C can begin on the cell surface, but the subcellular sites at which the PrP^C is converted to new PrP^{RES} remain unclear. Virtually all of the PrP^{RES} produced in cultured N2a neuroblastoma cells is internalized and rapidly truncated at the N-terminus by endolysosomal proteases (69). Evidence for similar events can be found in scrapie brain and lymphoid tissues (94). However, much of the PrP^{RES} is only visualized *in vivo* at the cell membrane where it usually remains full-length, suggesting that it may be formed and initially accumulated on the cell surface without being endocytosed and exposed to intracellular proteases.

Although isolated detergent-extracted PrP^{RES} can instigate PrP^C conversion and chronic infection in neuroblastoma cells, PrP^{RES} that is still associated with membranous vesicles is much more efficient at doing so per unit of PrP^{RES} (90,95). Cell-free conversion reactions have shown that when PrP^C is GPI-anchored to membranes, PrP^{RES} can much more readily induce PrP^C conversion when the two isoforms are attached to the same membrane (96,97). On the other hand, if the GPI-anchor of PrP^C is cleaved by a phospholipase, then it is free to be converted by PrP^{RES} in a separate membrane. Interestingly, PrP^C need not be fully dissociated from its membrane to be converted by PrP^{RES} on a separate membrane. For example, GPI-anchorless PrP^C can bind to certain membranes with the help of residues 34-94 in the flexible N-terminal domain and, in this configuration, can be converted by PrP^{RES} on separate membrane vesicles (96). Altogether, these findings support the view that the GPI-anchoring of PrP^C to membranes constrains its interactions with PrP^{RES} such that conversion is only efficient when PrP^{RES} is anchored *in cis* to the same membrane. However, in apparent contradiction to this conclusion are studies showing that TSE infectivity tightly bound to steel surfaces can readily induce infections *in vivo* (98). At present, it is not clear how to reconcile these observations unless cells can extract PrP^{RES}/infectivity from the wires. Another possibility is that a distinct orientation of steel-bound PrP^{RES}, perhaps with exposed GPI anchors, allows it to induce the conversion of membrane-bound PrP^C without dissociating from the steel.

CELL-TO-CELL SPREAD OF TSE PRIONS

Once an individual cell is propagating prions, a central unresolved issue is how the infection then spreads to other cells. Cell proximity appears to be important for efficient spread in cell culture (99). The greater apparent specific infectivity of infectivity associated with membrane-bound PrP^{RES} (95), as well as the greater efficiency of conversion when GPI-anchored PrP^C and PrP^{RES} are inserted into the same membranes (96,97), led us to propose that the cell-to-cell spread of infection might occur primarily via transfer of PrP^{RES}-containing membrane microparticles (Figure 7) (97). Fusion of such particles into recipient cells could insert PrP^{RES} into the plasma membrane in a topology compatible with conversion of GPI anchored PrP^C molecules.

Exosomes

Consistent with this idea are observations that PrP^C, PrP^{RES}, and scrapie infectivity can be released from cultured scrapie-infected cells in association with small (50–90 nm) vesicles called exosomes (100). Exosomes are assembled in cytoplasmic organelles known as multivesicular bodies and secreted via exocytosis (Figure 7). Released exosomes can then fuse with other cells and deliver their cargos. Appropriately, the topology of exosomes is such that exofacial membrane proteins such as PrP^{RES} would maintain an exofacial topology upon fusion with the plasmalemma of a new cell. Both non-neuronal and neuronal prion-infected cell lines can release exosomes that are infectious for mice, supporting the concept that exosomes may be a significant mechanism for the spread of these infections *in vivo* (100,101). However, extensive efforts have failed so far to visualize exosomes in brain tissue (78). Exosomes can be found in germinal centers of lymphoid tissues, where they derive from B cells and not follicular dendritic cells, the cell type which putatively amplifies infectivity. In scrapie infected follicles, B cell-derived exosomes lack demonstrable abnormal PrP (102).

Tunneling nanotubes

Another potential spreading mechanism is the transfer of membrane-associated PrP^{RES} between cells via recently-described entities called tunneling nanotubes (89,103,104). Tunneling nanotubes are thin membranous bridges that can form between cells and mediate the transfer of organelles, plasma membrane components (including GPI-anchored proteins), cytoplasmic molecules, and pathogens (Figure 7) (105). Interestingly, tunneling nanotubes can transport vesicles that, like those responsible for neuritic transport of PrP^{RES} (89), are small, acidic and of endosomal/lysosomal origin. Although their existence remains to be documented *in vivo*, tunneling nanotubes have been observed in a variety of cultured cell types (105). For example, murine retroviruses are known to exploit tunneling nanotube-like cell bridges to spread between cells. These viruses can induce the outgrowth of filopodia from uninfected cells to virus-infected cells and then migrate along the bridge back to the target cell. It is notable that murine retroviruses are also known to enhance the release of scrapie prions into the medium of cultured cells (106). In the latter study, the prions were found in exosome-like structures; however, it is possible that vesicular structures can also be derived from the shearing of tunneling nanotubes.

PrP-MEMBRANE ASSOCIATION AND PATHOGENESIS

The usual proximity between PrP molecules and cellular membranes raises the issue of the influence of these interactions in the neurodegenerative pathology of TSE diseases. The anchorless PrP transgenic mouse model provides striking evidence that, although the lack of GPI-anchored PrP does not prevent PrP^{RES} and prion accumulation, it profoundly alters the manifestations of scrapie infections (29). Indeed, most of the typical clinical and neuropathological characteristics of scrapie are either absent or greatly reduced in these mice despite the accumulation of brain PrP^{RES} to levels comparable to those in scrapie-infected wild-type mice. This reduced brain damage could be due either to a need for anchored PrP^C on brain cells for toxicity induced by PrP^{RES} and/or to a lower pathogenicity of PrP^{RES} amyloid plaques compared to the more dispersed, amorphous, and membrane-associated PrP^{RES} deposits seen in most other TSE/prion diseases. This latter situation would be consistent with the emerging view that in other protein misfolding diseases such as Alzheimer's disease, it is not amyloid plaques, but smaller misfolded protein oligomers that are the most neuropathologic (107,108). It is likely that potentially toxic protein aggregates are relatively benign when deposited in the extracellular space as plaques with relatively low surface area-to-mass ratios. Moreover, microglia tend to surround amyloid plaques and may seal them off from exposure to the rest of the brain tissue while attempting to degrade them [e.g., (109,110)]. This is not to say that PrP^{RES} amyloid deposits are innocuous, because they clearly can be associated with

severe pathogenic lesions and clinical disease. However, these pathogenic effects are different and appear to be slower to result in clinical deficits than those associated with diffuse types of PrP^{RES} deposits [(29) and B. Chesebro, personal communication].

In TSE-infected wild-type hosts expressing GPI-anchored PrP^C, a number of ultrastructural neuropathological lesions of neuronal and/or astrocyte membranes are considered pathognomonic. These include membrane proliferation and microfolding, highly abnormal coated pits, tubulovesicular bodies, and spiral membrane inclusions of axons (111). Other findings that are typical, but not specific for TSEs, include vacuolation, gliosis, degenerate processes, dystrophic axons, autophagic vacuoles, clumped synaptic vesicles, and neuronal death. TSE-associated pathology often involves membrane distortions in proximity to the accumulation of what has been aptly described as disease-associated PrP (PrP^d) because it can be labeled specifically in histological sections of infected hosts without determination of the various biochemical properties that are usually used to identify PrP^{RES}. PrP^d accumulation corresponds ultrastructurally with abnormal endocytosis, increased endo-lysosomes, and both finger-like extensions and invaginations (i.e., microfolding) of plasma membranes (Figure 8) (78). Extracellular accumulations of PrP^d are also observed, as well as suggestions of inter-cellular transfer of PrP^d between neurons and/or glia. PrP^d can appear to fill the narrow gap (~10 nm) between the closely opposed plasmalemmas (Figure 8A). Some aberrant membrane structures, notably tubulovesicular structures, appear to lack PrP^d (78). Tubulovesicular bodies are small (20–35 nm), irregular spherical or short tubular structures that are packed into dendrites and occasionally axon terminals (112,113). Tubovesicular body clusters have some resemblance to multivesicular bodies but differ in their smaller size, lack of a limiting membrane, and absence of PrP^d which suggests that they are not the same as the PrP^{RES}-containing exosomes that may mediate transfer of infectivity between cultured cells.

How might membrane-associated PrP^{RES} be neurotoxic?

The importance of GPI-anchoring of PrP molecules in TSE pathogenesis is likely connected mechanistically to the distortions of cellular membranes and membrane trafficking associated with TSE disease. When PrP^C is anchored to membranes by a GPI (or GPI-like) moiety, it typically assumes the α -helical conformation of native soluble PrP^C (114,115), unless its concentration is raised above a threshold level (116). In the latter situation, fully glycosylated, GPI-anchored PrP^C can oligomerize into a form with higher β -sheet content in raft-like membranes, but it is not clear whether the polypeptides penetrate the lipid bilayer. In the absence of GPI-anchors, full-length PrP^C and PrP90-231 can bind to lipid membranes and undergo major changes in conformation, protease-resistance and aggregation state (96,117–122). In doing so, such PrP molecules can disrupt the lipid bilayer (120,122) and, in the case of the GSS-associated mutant PrP fragment 82–146, form channels (118). Moreover, oligomers of full length anchorless PrP can be neurotoxic when added to culture media or inoculated into the brain (123). When anchorless PrP is artificially expressed in the cytoplasm rather than in the secretory pathway, its interactions with membranes correlates with cytotoxicity (119). Despite these multiple observations of seemingly unhealthy interactions between anchorless PrP molecules and membranes, the fact remains that transgenic mice that express anchorless PrP are normally healthy and, when infected with scrapie, have neuropathological manifestations that are quite different from those of wild-type mice. This again highlights the GPI anchor as a key arbiter in TSE pathogenesis *in vivo*.

Given that PrP^{RES} tends to be oligomeric, membrane-associated, and difficult for cells to degrade, it is possible that the mere accumulation of PrP^{RES} aggregates on membranes compromises fundamental membrane functions. Because most PrP^{RES} molecules have GPI moieties (124), the GPI anchoring of PrP^{RES} oligomers to membranes should be multivalent. Multivalent membrane interactions should limit the quaternary interactions between PrP^{RES}

molecules within the plane of the membrane and may promote sheet-like lateral structures (125) compatible with the 2-D PrP^{RES} crystals visualized by Wille et al. (45). On the other hand, whole-cell atomic force microscopy suggests that fibrillar PrP^{RES} aggregates might be present on the surface of scrapie-infected cells in culture (126).

Whatever the preferred PrP^{RES} quaternary structure(s), it is likely that the accumulation of any relatively large PrP^{RES} aggregate that is multiply anchored to membranes could distort its local structure, composition, flexibility, fluidity, dynamics, integrity and, hence, functionality. The presence of PrP^d in abnormal spiral clefts at the cell surface and in endosome-derived subcellular structures points to aberrant attempts by cells to internalize membranes containing PrP^d aggregates (Figure 8). Membranes containing intense PrP^d accumulation can also be unusually linear and close to short extracellular fibrils (Figure 8E). This suggests that PrP^d accumulation might impart an increased rigidity to membranes which could affect PrP^d internalization and degradation as well as normal endocytic processes. PrP^d often appears to be associated with ubiquitin and clathrin on opposite sides of lipid bilayers of spiral clefts and internalized coated membranous structures (78). Thus ubiquitin tagging and the membrane-inverting forces of clathrin could play roles in the generation of these distorted structures. The packing of PrP^d between closely opposed membranes of adjacent cells (Figure 8A) and into narrow spiral clefts (78) also suggests that PrP^d, alone or in conjunction with other molecules, may cause abnormal adhesion between membrane surfaces.

A pathological role for GPI-anchored PrP^C on neurons?

Following infection, transgenic PrP knockout mice that lack PrP altogether (127) or turn off PrP^C expression in adulthood (128) do not exhibit the symptoms of TSE disease. Thus, although other recent data suggest that some aspects of neurological disease associated with inherited PrP mutations might be due to deficits in the apparent neuroprotective activities of PrP^C (129), TSE pathogenesis does not appear to be due simply to a loss of PrP^C function. On the contrary, there is evidence that clinical disease may require the presence of PrP^C as well as PrP^{RES}. For instance, wild-type brain tissue grafts in scrapie-infected PrP knockout mice produce PrP^{RES} that does not cause neuropathology in surrounding tissue that lacks PrP^C (130). Moreover, Mallucci and colleagues have shown that cessation of PrP^C expression in the neurons of adult scrapie-infected transgenic mice reverses spongiosis and delays clinical disease long term without stopping further accumulation of PrP^{RES} produced in other cell types (131). In addition, transgenic mice expressing PrP^C exclusively in neurons are susceptible to scrapie (132). These results suggest that neuronal PrP^C expression is needed to mediate most PrP^{RES}-induced neuropathogenesis. However, this is not always true because Raeber and colleagues have shown that TSE disease can develop in scrapie-infected transgenic mice that express PrP^C only in astrocytes and not to any detectable extent in neurons (133). The reason for the apparent discrepancy between the Mallucci and Raeber results is not clear but could relate to differences in the strain and species of prion, the sequence of expressed PrP^C, and/or the levels of PrP^C expression in the respective transgenic mouse models.

Direct and indirect mechanisms of PrP^{RES} neurotoxicity

Collectively, these studies leave open the possibilities of both direct and indirect mechanisms of PrP^{RES} neurotoxicity, which may vary in importance between various TSE disease models or neuroanatomical sites within hosts. Direct PrP^{RES} toxicity might be mediated by the membrane disturbances described above, which could have profound effects on processes such as neuronal homeostasis, intercellular contacts, synaptogenesis, synaptic functions, and axonal transport. Indirect effects of PrP^{RES} could be mediated by perturbations of glial functions that in turn cause neuronal lesions (112,134,135). Alternatively PrP^{RES} could corrupt, rather than knock out, PrP^C function (136). Transgenic mice expressing various mutant PrP^C molecules have revealed that perturbations of PrP^C structure, expression level or functions alone can cause

neurological disease, even without TSE infection [reviewed in (136)]. It follows then that the accumulation of PrP^{RES} might cause disease by altering the metabolism or activities of PrP^C. To decipher these possibilities it would be helpful to understand the physiological function of PrP^C, but this remains elusive (104,137). Nonetheless, a number of studies have provided evidence that PrP^C has cytoprotective, anti-apoptotic activities against various cellular stresses [reviewed in (104,136,137)]. At the same time, injections of PrP antibodies into the brain can lead to neuronal apoptosis providing evidence that PrP^C crosslinking or interference with PrP^C-ligand binding can have adverse consequences (138). Thus, it is possible that contact between PrP^{RES} and PrP^C could have similar effects in TSE-infected individuals. It has been proposed that PrP^C interacts with a physiological ligand in two sites and that disruption of one of those interactions can elicit cell death (139). Still another possibility is that an intermediate or byproduct of PrP^{RES} formation is more neurotoxic than mature PrP^{RES} itself. This scenario could account for the enhanced neuropathogenesis observed in scrapie-infected hosts expressing GPI-anchored PrP^C in neurons.

Interestingly, small amounts of PrP^{RES} have been detected in the cytosol and can inhibit the ubiquitin-proteasome system, with oligomeric aggregation intermediates being the most inhibitory in this system (140). At this point, it is unclear which of these direct and indirect mechanisms of PrP^{RES}-associated neuropathogenesis, or some combination thereof, is most important in TSE diseases. It seems unlikely that a single discrete mechanism is at play in all TSE diseases, given their phenotypic diversity.

STRETCHING THE REALM OF PRIONS

Since Prusiner's coining of the term prion and Wickner's expansion of the prion concept to fungal epigenetics, a number of biological phenomena have been described as prions or prion-like. These include both functional [reviewed in (141,142)] and disease-associated amyloids in a variety of organisms. The prions of *Saccharomyces cerevisiae* and other fungi have become the best characterized both genetically and biochemically [reviewed in (143)]. The [URE3], [PSI⁺], [PIN⁺] and [Het-s] prions are amyloid forms of normally soluble proteins, Ure2p, Sup35p, Rnq1p and HETs, respectively. The prion forms of Ure2p and Sup35p are inactive and result in loss-of-function phenotypes for the cell. Rnq1p amyloid primes yeast for [PSI⁺] formation (144), but the function of soluble Rnq1p is unknown. The HETs protein function is also unknown but its amyloid (prion) form is active in mediating heterokaryon incompatibility in *Podospora anserina* (145). Thus, unlike most prions, the [Het-s] prion may play a positive physiological role in the host organism. Wickner and Roberts have also reported evidence for a novel non-amyloid prion of *S. cerevisiae*, [β], which takes the form of a self-activating vacuolar protease B that is necessary for meiosis and aids survival in the stationary phase of the cell cycle. Even a self-activating protein regulatory network, as opposed to an altered form of an individual protein, has been shown to share many properties with fungal prions. In this case, a self-activating MAP kinase cascade appears to be responsible for a non-Mendelian hereditary unit called [C] which is responsible for inheritance, and possibly the cell-to-cell spread, of the crippled growth phenotype in *P. anserina* (146).

Whether in fungi or mammals, the ability of amyloids to nucleate or seed their own growth gives them self-propagating activity that is at least partly analogous to that of prions. Indeed, some experimental amyloidoses in mammals have shown evidence of being transmissible in the sense that amyloid taken from an amyloidotic individual can sometimes greatly accelerate amyloidosis in another individual. However, it is important to emphasize that such "transmissions" have only been shown under unnatural, experimental conditions in which the recipient animal is highly primed for susceptibility to amyloidosis and would be expected to develop amyloidosis spontaneously given time.

AA amyloidosis

One prototypic example of an apparently transmissible amyloid disease is AA amyloidosis, a malady of humans and animals involving the widespread accumulation of serum amyloid A (AA) protein amyloid, especially in the kidney, liver and spleen. Most cases of AA amyloidosis in mammals appear to occur spontaneously due to chronic inflammation or genetic peculiarities that elevate blood levels of AA and predispose the organism to AA amyloid formation.

However, it has long been known that inoculation of extracts of material from amyloidotic mice (a.k.a., amyloid enhancing factor) into other mice can rapidly induce amyloidosis as long as the recipients are themselves strongly primed for amyloidosis by proinflammatory treatments such as silver nitrate injections (147). Evidence now points to aggregated AA as amyloid enhancing factor (148). As with the synthetic prion experiments discussed above (19), these experiments raise the question of whether the amyloid inoculum initiates disease, as is clearly the case with legitimate TSE prions, or merely enhances an ongoing pathogenic process.

AA amyloidosis is wreaking havoc in the captive cheetah population, complicating efforts to rescue this endangered species from extinction (149,150). Amyloidotic cheetahs shed AA amyloid in the feces, and this fecal amyloid can accelerate AA amyloidosis when injected intravenously into silver nitrate-primed mice (151). Given that murine AA amyloid can accelerate amyloidosis in mice when administered orally, these results suggest a plausible fecal-oral route for the natural transmission of AA amyloidosis in cheetahs. More study will be required to demonstrate the actuality of such a transmission cycle. If proven to be true, cheetah AA amyloidosis might become the first known naturally transmissible, non-PrP prion in mammals. Even so, the question of whether the transmitted amyloid initiates or enhances amyloidosis in naïve cheetahs will remain. Moreover, one striking characteristic of captive cheetahs relative to those in the wild is their chronic inflammation and high blood AA levels (150). These factors could make them susceptible to spontaneous amyloidosis, as is the case with silver nitrate-treated mice. If so, then the high incidence of amyloidosis in captive cheetahs might be due to spontaneous disease rather than infections with amyloid from other animals.

Apolipoprotein AII (ApoAII) amyloidosis

ApoAII is an amyloidogenic protein that causes mouse senile amyloidosis and a hereditary human disease due to a mutation in the *APOA2* gene. Like experimental AA amyloidosis, mouse senile amyloidosis affects visceral organs and can be stimulated by the experimental administration of exogenous amyloid via the gastrointestinal tract, possibly after consumption of ApoAII amyloid in the feces of amyloidotic cagemates (152). ApoAII amyloid accumulation also occurs spontaneously in aged mice, raising the possibility that inoculated ApoAII amyloid merely accelerates systemic amyloidosis.

A β amyloidoses

In Alzheimer's disease (AD), cerebral A β angiopathy, and, to some extent, in many aged humans who are cognitively normal, A β , a small proteolytic fragment of the A β precursor protein (β APP), accumulates in amyloid deposits in the brain. Whether the amyloid form of A β is the primary pathogenic entity in AD remains a matter of debate, with recent evidence leaning toward smaller sub-amyloid A β oligomers being more neurotoxic (107,108). Although there is no evidence that AD *per se* is transmissible, studies in transgenic mouse models of AD have suggested that A β amyloidosis can be stimulated by intracerebral injections of brain extracts from AD patients or amyloidotic β APP transgenic mice (153). Once again, as was the case with the AA and ApoAII amyloidosis inoculation studies noted above, it is unclear whether the A β amyloid caused amyloidosis or merely accelerated an ongoing pathogenic process because the transgenic recipients ultimately develop deposits spontaneously without inoculation exogenous of the A β amyloid extracts. Another major unresolved issue, when

comparing this amyloid-inducing activity with a TSE prion disease, is the extent to which the induced A β -amyloidotic lesions can spread from localized sites of seeding by the inoculum to other sites within the host.

CPEB

Another protein that has been described as having prion-like properties is cytoplasmic polyadenylation element binding protein (CPEB) (154). The behavior of ectopically expressed neuronal CPEB or its N-terminal domain in yeast led Si and coworkers to propose that distinct CPEB states in neurons might serve as a mechanism for stabilizing plastic changes in synapses. In their model, a self-perpetuating aggregated state of CPEB is induced in activated synapses, altering local mRNA translation and helping to sustain long term facilitation. Although this is an intriguing potential mechanism for synaptic regulation, it would be difficult to consider it a prion-like phenomenon in neurons because of the lack of CPEB-mediated transmission of the phenotypic change to other cells and organisms.

Amyloid spreading mechanisms?

Consideration of the above examples of prion or prion-like entities raises the key issue of spreading mechanisms. It is now commonplace to find proteins that can exist in two or more states with at least one of those states being able to perpetuate itself via self-seeding or autocatalytic activity. Indeed, most proteins are predicted to be capable of forming amyloids under certain conditions (142). As noted above, the ability of a self-perpetuating protein state to spread between cells and organisms is a hallmark of prions. In yeast and at least some other fungi, the spread of cytoplasmic prions can occur through cytoplasmic exchange or transfer during cell division, mating (in which cells fuse), or cytoduction (a largely experimental abortive mating procedure in which cytoplasmic mixing occurs while nuclear fusion is blocked). In mammals, horizontal prion spreading mechanisms would tend to be much more complex, involving host-to-host transfers through the environment and tissue barriers, and cell-to-cell transfers without overt cytoplasmic mixing. With most mammalian cells, mechanisms for the horizontal exchange of cytoplasmic molecules larger than 1 kDa are not readily apparent, except perhaps in some cases for exosomes and tunneling nanotubes as described above. The apparent lack of such mechanisms would seem to reduce the likelihood of finding purely cytoplasmic prions in mammals.

As noted above, many mammalian diseases lead to the accumulation of extracellular, rather than cytoplasmic, amyloid which might more readily migrate between cells to spread within tissues and hosts. With inducible systemic amyloidoses, such as AA and ApoAII amyloidoses, hematogenous spread appears to occur. Blood-borne amyloid is particularly capable of penetrating some tissues via fenestrated capillaries, which allow passage of large molecules such as proteins (155). On the other hand, access of such blood-borne amyloids to the central nervous system is severely limited. Furthermore, it is not yet clear whether extracellular amyloids, such as A β amyloid, that are produced within the brain are capable of spreading effectively from their sites of initial deposition to other regions. If it turns out to be true that various brain amyloids have little capacity to propagate throughout the central nervous system, or to invade the CNS from peripheral tissues, then the hazards of localized amyloid inoculations will likely be small. However, if amyloids can propagate throughout the CNS like TSE prions, then there might be real reason to fear the possibility of amyloid infections. For the time being it appears that, relative to other self-propagating protein aggregates, TSE prions are unusually adept at spreading between and within mammalian hosts by practical routes. TSEs are also the only prion diseases known to involve a protein that is normally GPI anchored, a feature that accounts at least in part for the unique biology and neurovirulence of these devastating transmissible diseases.

KEY TERMS/DEFINITIONS

1. **prion**: an infectious protein or self-propagating protein-based element of epigenetic inheritance with the capacity to spread between hosts
2. **protein misfolding disease**: disease associated with the deposition of a misfolded host protein
3. **amyloid**: protein fibrils exhibiting a cross β -core structure and specific staining characteristics with diagnostic dyes (thioflavins S and T, Congo red)
4. **protofilament**: fibrillar protein polymers that form amyloid fibrils by lateral association

SUMMARY LIST

1. Cell-free propagation of TSE prions has effectively ruled out the need for an exogenous, pathogen-encoding nucleic acid, but polyanions such as poly A RNA, can play an important role in prion replication.
2. The 3D structure of TSE prions remains largely a mystery, but recent technical advances have greatly enhanced the understanding of the molecular architecture of yeast prions and other amyloid fibrils.
3. The ability to propagate within and between hosts is a key characteristic of prions which distinguishes them from other autocatalytic protein states.
4. The GPI anchor distinguishes prion protein from other amyloidogenic proteins and has strong influences on TSE pathogenesis.
5. TSE pathogenesis involves major membrane disturbances in the brain, which may in part be mediated by the accumulation of abnormal GPI-anchored PrP molecules.
6. Several non-PrP-based mammalian amyloidoses appear to be transmissible under experimental conditions. Further studies will be required to determine if transmission of such amyloids between hosts under practical circumstances poses a risk to humans or animal health.

FUTURE ISSUES

1. Complete molecular composition of TSE prions and basis for poor infectivity of amyloid fibrils derived from recombinant PrP^C
2. 3D structures of prions and their different strains
3. Neurotoxic entities in TSE diseases and other protein misfolding diseases
4. Critical neuropathogenic pathways in TSE diseases
5. In vivo mechanism(s) of cell-to-cell spread of TSE prions
6. Natural spreading capacities of disease-associated non-PrP amyloids and amyloid-like protein aggregates: Do they pose risks of infection?
7. Effective diagnostic tests and therapies for TSE diseases
8. How widespread and diverse are prions in biology?

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Drs. Valerie Sim, Kelly Barton, Winslow Caughey, Leah Christensen and Kim Hasenkrug for helpful comments on this manuscript. Gary Hettrick provided excellent graphics assistance. This work was supported by the Intramural Research Program of the NIAID, NIH.

ABBREVIATIONS/ACRONYMS

PrP ^C	normal cellular isoform of the prion protein (PrP)
PrP ^{RES}	abnormal, partially protease-resistant, prion disease-associated isoform of PrP; largely synonymous with PrP ^{Sc}
PMCA	protein misfolding cyclic amplification
rPrP-PMCA	recombinant PrP PMCA
QuIC	quaking-induced conversion; an rPrP-PMCA-like reaction that is shaken rather than sonicated
PrP ^d	disease-specific isoform of PrP detected by immunological staining of tissues without implying any other biochemical or infectious properties
TSE	transmissible spongiform encephalopathy
GPI	glycophosphatidylinositol
PK	proteinase K

LITERATURE CITED

1. Griffith JS. Self-replication and scrapie. *Nature* 1967;215:1043–4. [PubMed: 4964084]
2. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. *Science* 1982;216:136–44. [PubMed: 6801762]
3. Castilla J, Saa P, Hetz C, Soto C. In vitro generation of infectious scrapie prions. *Cell* 2005;121:195–206. [PubMed: 15851027]
4. Deleault NR, Harris BT, Rees JR, Supattapone S. Formation of native prions from minimal components *in vitro*. *Proc Natl Acad Sci U S A* 2007;104:9741–6. [PubMed: 17535913]
5. Wickner RB. [URE3] as an altered URE2 protein: evidence for a prion analog in *Saccharomyces cerevisiae* [see comments]. *Science* 1994;264:566–9. [PubMed: 7909170]
6. Chien P, Weissman JS, DePace AH. Emerging principles of conformation-based prion inheritance. *Annu Rev Biochem* 2004;73:617–56. [PubMed: 15189155]
7. Prusiner SB, Groth DF, Bolton DC, Kent SB, Hood LE. Purification and structural studies of a major scrapie prion protein. *Cell* 1984;38:127–34. [PubMed: 6432339]
8. Bessen RA, Kocisko DA, Raymond GJ, Nandan S, Lansbury PT Jr, Caughey B. Nongenetic propagation of strain-specific phenotypes of scrapie prion protein. *Nature* 1995;375:698–700. [PubMed: 7791905]
9. Kocisko DA, Come JH, Priola SA, Chesebro B, Raymond GJ, et al. Cell-free formation of protease-resistant prion protein. *Nature* 1994;370:471–4. [PubMed: 7913989]
10. Kocisko DA, Priola SA, Raymond GJ, Chesebro B, Lansbury PT Jr, Caughey B. Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. *Proc Natl Acad Sci USA* 1995;92:3923–7. [PubMed: 7732006]
11. Raymond GJ, Hope J, Kocisko DA, Priola SA, Raymond LD, et al. Molecular assessment of the transmissibilities of BSE and scrapie to humans. *Nature* 1997;388:285–8. [PubMed: 9230438]
12. Caughey B, Kocisko DA, Raymond GJ, Lansbury PT. Aggregates of scrapie associated prion protein induce the cell-free conversion of protease-sensitive prion protein to the protease-resistant state. *Chem & Biol* 1995;2:807–17. [PubMed: 8807814]

13. Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, et al. The most infectious prion protein particles. *Nature* 2005;437:257–61. [PubMed: 16148934]
14. Callahan MA, Xiong L, Caughey B. Reversibility of scrapie-associated prion protein aggregation. *J Biol Chem* 2001;276:28022–8. [PubMed: 11375994]
15. Gadjusek DC. Transmissible and nontransmissible amyloidoses: Autocatalytic post-translational conversion of host precursor proteins to beta-pleated configurations. *J Neuroimmunol* 1988;20:95–110. [PubMed: 3143742]
16. Jarrett JT, Lansbury PT Jr. Seeding “One-Dimensional Crystallization” of Amyloid: A Pathogenic Mechanism in Alzheimer’s Disease and Scrapie? *Cell* 1993;73:1055–8. [PubMed: 8513491]
17. Caughey B, Raymond GJ, Kocisko DA, Lansbury PT Jr. Scrapie infectivity correlates with converting activity, protease resistance, and aggregation of scrapie-associated prion protein in guanidine denaturation studies. *J Virol* 1997;71:4107–10. [PubMed: 9094691]
18. Hill AF, Antoniou M, Collinge J. Protease-resistant prion protein produced in vitro lacks detectable infectivity. *J Gen Virol* 1999;80:11–4. [PubMed: 9934677]
19. Legname G, Baskakov IV, Nguyen HO, Riesner D, Cohen FE, et al. Synthetic mammalian prions. *Science* 2004;305:673–6. [PubMed: 15286374]
20. Legname G, Nguyen HO, Baskakov IV, Cohen FE, DeArmond SJ, Prusiner SB. Strain-specified characteristics of mouse synthetic prions. *Proc Natl Acad Sci U S A* 2005;102:2168–73. [PubMed: 15671162]
21. Hsiao KK, Groth D, Scott M, Yang SL, Serban H, et al. Serial transmission in rodents of neurodegeneration from transgenic mice expressing mutant prion protein. *Proc Natl Acad Sci U S A* 1994;91:9126–30. [PubMed: 7916462]
22. Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. *Nature* 2001;411:810–3. [PubMed: 11459061]
23. Weber P, Giese A, Piening N, Mitteregger G, Thomzig A, et al. Cell-free formation of misfolded prion protein with authentic prion infectivity. *Proc Natl Acad Sci U S A* 2006;103:15818–23. [PubMed: 17030802]
24. Saa P, Castilla J, Soto C. Ultra-efficient replication of infectious prions by automated protein misfolding cyclic amplification. *J Biol Chem* 2006;281:35245–52. [PubMed: 16982620]
25. Geoghegan JC, Valdes PA, Orem NR, Deleault NR, Williamson RA, et al. Selective incorporation of polyanionic molecules into hamster prions. *J Biol Chem* 2007;282:36341–53. [PubMed: 17940287]
26. Atarashi R, Wilham JM, Christensen L, Hughson AG, Moore RA, et al. Simplified ultrasensitive prion detection by recombinant PrP conversion with shaking. *Nat Methods* 2008;5:211–2. [PubMed: 18309304]
27. Atarashi R, Moore RA, Sim VL, Hughson AG, Dorward DW, et al. Ultrasensitive detection of scrapie prion protein using seeded conversion of recombinant prion protein. *Nat Methods* 2007;4:645–50. [PubMed: 17643109]
28. Colby DW, Zhang Q, Wang S, Groth D, Legname G, et al. Prion detection by an amyloid seeding assay. *Proc Natl Acad Sci U S A* 2007;104:20914–9. [PubMed: 18096717]
29. Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, et al. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. *Science* 2005;308:1435–9. [PubMed: 15933194]
30. Tuzi NL, Cancellotti E, Baybutt H, Blackford L, Bradford B, et al. Host PrP glycosylation: a major factor determining the outcome of prion infection. *PLoS Biol* 2008;6:e100. [PubMed: 18416605]
31. Neuendorf E, Weber A, Saalmueller A, Schatzl H, Reifenberg K, et al. Glycosylation deficiency at either one of the two glycan attachment sites of cellular prion protein preserves susceptibility to bovine spongiform encephalopathy and scrapie infections. *J Biol Chem* 2004;279:53306–16. [PubMed: 15448157]
32. Merz PA, Somerville RA, Wisniewski HM, Iqbal K. Abnormal fibrils from scrapie-infected brain. *Acta Neuropathol* 1981;54:63–74. [PubMed: 7195134]
33. Prusiner SB, McKinley MP, Bowman KA, Bendheim PE, Bolton DC, et al. Scrapie prions aggregate to form amyloid-like birefringent rods. *Cell* 1983;35:349–58. [PubMed: 6418385]
34. Sim VL, Caughey B. Ultrastructures and strain comparison of under-glycosylated scrapie prion fibrils. *Neurobiol Aging*. 2008[Epub ahead of print]

35. Caughey BW, Dong A, Bhat KS, Ernst D, Hayes SF, Caughey WS. Secondary structure analysis of the scrapie-associated protein PrP 27–30 in water by infrared spectroscopy. *Biochemistry* 1991;30:7672–80. [PubMed: 1678278]
36. Pan K-M, Baldwin M, Nguyen J, Gasset M, Serban A, et al. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion protein. *Proc Natl Acad Sci USA* 1993;90:10962–6. [PubMed: 7902575]
37. Caughey B, Raymond GJ, Bessen RA. Strain-dependent differences in beta-sheet conformations of abnormal prion protein. *J Biol Chem* 1998;273:32230–5. [PubMed: 9822701]
38. Spassov S, Beekes M, Naumann D. Structural differences between TSEs strains investigated by FT-IR spectroscopy. *Biochim Biophys Acta* 2006;1760:1138–49. [PubMed: 16730908]
39. Bessen RA, Marsh RF. Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. *J Virol* 1994;68:7859–68. [PubMed: 7966576]
40. Somerville RA, Hamilton S, Fernie K. Transmissible spongiform encephalopathy strain, PrP genotype and brain region all affect the degree of glycosylation of PrP^{Sc}. *J Gen Virol* 2005;86:241–6. [PubMed: 15604453]
41. Kascak, R.J.; Rubenstein, R.; Carp, R.I. Evidence for Biological and Structural Diversity Among Scrapie Strains. In: Chesebro, B., editor. *Transmissible Spongiform Encephalopathies: Scrapie, BSE and Related Human Disorders*. Berlin-Heidelberg: Springer-Verlag; 1991. p. 139-152.
42. Parchi P, Castellani R, Capellari S, Ghetti B, Young K, et al. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. *Ann Neurol* 1996;39:767–78. [PubMed: 8651649]
43. Collinge J, Sidle KCL, Meads J, Ironside J, Hill AF. Molecular analysis of prion strain variation and the aetiology of “new variant” CJD. *Nature* 1996;383:685–90. [PubMed: 8878476]
44. Safar J, Wille H, Itri V, Groth D, Serban H, et al. Eight prion strains have PrP(Sc) molecules with different conformations [see comments]. *Nat Med* 1998;4:1157–65. [PubMed: 9771749]
45. Wille H, Michelitsch MD, Guenebaut V, Supattapone S, Serban A, et al. Structural studies of the scrapie prion protein by electron crystallography. *Proc Natl Acad Sci U S A* 2002;99:3563–8. [PubMed: 11891310]
46. Govaerts C, Wille H, Prusiner SB, Cohen FE. Evidence for assembly of prions with left-handed beta-helices into trimers. *Proc Natl Acad Sci U S A* 2004;101:8342–7. [PubMed: 15155909]
47. Demarco ML, Daggett V. From conversion to aggregation: protofibril formation of the prion protein. *Proc Natl Acad Sci U S A* 2004;101:2293–8. [PubMed: 14983003]
48. Demarco ML, Silveira J, Caughey B, Daggett V. Structural Properties of Prion Protein Protofibrils and Fibrils: An Experimental Assessment of Atomic Models. *Biochemistry* 2006;45:15573–82. [PubMed: 17176078]
49. Lu X, Wintrodde PL, Surewicz WK. Beta-sheet core of human prion protein amyloid fibrils as determined by hydrogen/deuterium exchange. *Proc Natl Acad Sci U S A* 2007;104:1510–5. [PubMed: 17242357]
50. Cobb NJ, Sonnichsen FD, McHaourab H, Surewicz WK. Molecular architecture of human prion protein amyloid: a parallel, in-register beta-structure. *Proc Natl Acad Sci U S A* 2007;104:18946–51. [PubMed: 18025469]
51. Helmus JJ, Surewicz K, Nadaud PS, Surewicz WK, Jaroniec CP. Molecular conformation and dynamics of the Y145Stop variant of human prion protein in amyloid fibrils. *Proc Natl Acad Sci U S A* 2008;105:6284–9. [PubMed: 18436646]
52. Lim KH, Nguyen TN, Damo SM, Mazur T, Ball HL, et al. Solid-state NMR structural studies of the fibril form of a mutant mouse prion peptide PrP89-143(P101L). *Solid State Nucl Magn Reson* 2006;29:183–90. [PubMed: 16256316]
53. Baxa U, Wickner RB, Steven AC, Anderson DE, Marekov LN, et al. Characterization of beta-sheet structure in Ure2p1-89 yeast prion fibrils by solid-state nuclear magnetic resonance. *Biochemistry* 2007;46:13149–62. [PubMed: 17953455]
54. Shewmaker F, Ross ED, Tycko R, Wickner RB. Amyloids of shuffled prion domains that form prions have a parallel in-register beta-sheet structure. *Biochemistry* 2008;47:4000–7. [PubMed: 18324784]
55. Shewmaker F, Wickner RB, Tycko R. Amyloid of the prion domain of Sup35p has an in-register parallel beta-sheet structure. *Proc Natl Acad Sci U S A* 2006;103:19754–9. [PubMed: 17170131]

56. Wickner RB, Dyda F, Tycko R. Amyloid of Rnq1p, the basis of the [PIN⁺] prion, has a parallel in-register beta-sheet structure. *Proc Natl Acad Sci U S A* 2008;105:2403–8. [PubMed: 18268327]
57. Krishnan R, Lindquist SL. Structural insights into a yeast prion illuminate nucleation and strain diversity. *Nature* 2005;435:765–72. [PubMed: 15944694]
58. Luhrs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, et al. 3D structure of Alzheimer's amyloid-beta(1–42) fibrils. *Proc Natl Acad Sci U S A* 2005;102:17342–7. [PubMed: 16293696]
59. Ritter C, Maddelein ML, Siemer AB, Luhrs T, Ernst M, et al. Correlation of structural elements and infectivity of the HET-s prion. *Nature* 2005;435:844–8. [PubMed: 15944710]
60. Wasmer C, Lange A, Van MH, Siemer AB, Riek R, Meier BH. Amyloid fibrils of the HET-s(218–289) prion form a beta solenoid with a triangular hydrophobic core. *Science* 2008;319:1523–6. [PubMed: 18339938]
61. Toyama BH, Kelly MJ, Gross JD, Weissman JS. The structural basis of yeast prion strain variants. *Nature* 2007;449:233–7. [PubMed: 17767153]
62. Tanaka M, Collins SR, Toyama BH, Weissman JS. The physical basis of how prion conformations determine strain phenotypes. *Nature* 2006;442:585–9. [PubMed: 16810177]
63. Sun Y, Breydo L, Makarava N, Yang Q, Bocharova OV, Baskakov IV. Site-specific conformational studies of prion protein (PrP) amyloid fibrils revealed two cooperative folding domains within amyloid structure. *J Biol Chem* 2007;282:9090–7. [PubMed: 17244617]
64. Anderson M, Bocharova OV, Makarava N, Breydo L, Salnikov VV, Baskakov IV. Polymorphism and ultrastructural organization of prion protein amyloid fibrils: an insight from high resolution atomic force microscopy. *J Mol Biol* 2006;358:580–96. [PubMed: 16519898]
65. Nelson R, Sawaya MR, Balbirnie M, Madsen AO, Riek C, et al. Structure of the cross-beta spine of amyloid-like fibrils. *Nature* 2005;435:773–8. [PubMed: 15944695]
66. Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, et al. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. *Nature* 2007;447:453–7. [PubMed: 17468747]
67. Chiesa R, Harris DA. Prion diseases: what is the neurotoxic molecule? *Neurobiol Dis* 2001;8:743–63. [PubMed: 11592845]
68. Caughey B, Raymond GJ. The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. *J Biol Chem* 1991;266:18217–23. [PubMed: 1680859]
69. Caughey B, Raymond GJ, Ernst D, Race RE. N-terminal truncation of the scrapie-associated form of PrP by lysosomal protease(s): implications regarding the site of conversion of PrP to the protease-resistant state. *J Virol* 1991;65:6597–603. [PubMed: 1682507]
70. Borchelt DR, Taraboulos A, Prusiner SB. Evidence for synthesis of scrapie prion protein in the endocytic pathway. *J Biol Chem* 1992;267:16188–99. [PubMed: 1353761]
71. Wong C, Xiong L-W, Horiuchi M, Raymond LD, Wehrly K, et al. Sulfated glycans and elevated temperature stimulate PrP^{Sc} dependent cell-free formation of protease-resistant prion protein. *EMBO J* 2001;20:377–86. [PubMed: 11157745]
72. Horonchik L, Tzaban S, Ben Zaken O, Yedidia Y, Rouvinski A, et al. Heparan sulfate is a cellular receptor for purified infectious prions. *J Biol Chem* 2005;280:17062–7. [PubMed: 15668247]
73. Shaked GM, Meiner Z, Avraham I, Taraboulos A, Gabizon R. Reconstitution of prion infectivity from solubilized protease-resistant PrP and nonprotein components of prion rods. *J Biol Chem* 2001;276:14324–8. [PubMed: 11152454]
74. Leucht C, Simoneau S, Rey C, Vana K, Rieger R, et al. The 37 kDa/67 kDa laminin receptor is required for PrP(Sc) propagation in scrapie-infected neuronal cells. *EMBO Rep* 2003;4:290–5. [PubMed: 12634848]
75. Taraboulos A, Scott M, Semenov A, Avraham D, Laszlo L, Prusiner SB. Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. *J Cell Biol* 1995;129:121–32. [PubMed: 7698979]
76. Pani A, Norfo C, Abete C, Mulas C, Putzolu M, et al. Antiprion activity of cholesterol esterification modulators: a comparative study using ex vivo sheep fibroblasts and lymphocytes and mouse neuroblastoma cell lines. *Antimicrob Agents Chemother* 2007;51:4141–7. [PubMed: 17709472]


77. Naslavsky N, Shmeeda H, Friedlander G, Yanai A, Futerman AH, et al. Sphingolipid depletion increases formation of the scrapie prion protein in neuroblastoma cells infected with prions. *J Biol Chem* 1999;274:20763–71. [PubMed: 10409615]
78. Jeffrey M, McGovern G, Goodsir CM, Gonzalez L. Strain-Associated Variations in Abnormal PrP Trafficking of Sheep Scrapie. *Brain Pathol.* 2008[Epub ahead of print]
79. McKinley MP, Meyer RK, Kenaga L, Rahbar F, Cotter R, et al. Scrapie prion rod formation in vitro requires both detergent extraction and limited proteolysis. *J Virol* 1991;65:1340–51. [PubMed: 1704926]
80. Bellinger-Kawahara CG, Kempner E, Groth D, Gabizon R, Prusiner SB. Scrapie prion liposomes and rods exhibit target sizes of 55,000 Da. *Virology* 1988;164:537–41. [PubMed: 3130718]
81. Deleault NR, Geoghegan JC, Nishina K, Kasczak R, Williamson RA, Supattapone S. Protease-resistant prion protein amplification reconstituted with partially purified substrates and synthetic polyanions. *J Biol Chem* 2005;280:26873–9. [PubMed: 15917229]
82. Ben-Zaken O, Tzaban S, Tal Y, Horonchik L, Esko JD, et al. Cellular heparan sulfate participates in the metabolism of prions. *J Biol Chem* 2003;278:40041–9. [PubMed: 12871949]
83. Mabbott NA, MacPherson GG. Prions and their lethal journey to the brain. *Nat Rev Microbiol* 2006;4:201–11. [PubMed: 16462753]
84. Aguzzi A, Sigurdson C, Heikenwaelder M. Molecular mechanisms of prion pathogenesis. *Annu Rev Pathol* 2008;3:11–40. [PubMed: 18233951]
85. Prinz M, Heikenwalder M, Junt T, Schwarz P, Glatzel M, et al. Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion. *Nature* 2003;425:957–62. [PubMed: 14562059]
86. Siso S, Jeffrey M, Gonzalez L. Neuroinvasion in sheep transmissible spongiform encephalopathies: the role of the haematogenous route. *Neuropathol Appl Neurobiol.* 2008[Epub ahead of print]
87. Houston F, McCutcheon S, Goldmann W, Chong A, Foster J, et al. Prion diseases are efficiently transmitted by blood transfusion in sheep. *Blood.* 2008[Epub ahead of print]
88. Bartz JC, Kincaid AE, Bessen RA. Rapid prion neuroinvasion following tongue infection. *J Virol* 2003;77:583–91. [PubMed: 12477862]
89. Magalhaes AC, Baron GS, Lee KS, Steele-Mortimer O, Dorward D, et al. Uptake and neuritic transport of scrapie prion protein coincident with infection of neuronal cells. *J Neurosci* 2005;25:5207–16. [PubMed: 15917460]
90. Greil CS, Vorberg IM, Ward AE, Meade-White KD, Harris DA, Priola SA. Acute cellular uptake of abnormal prion protein is cell type and scrapie-strain independent. *Virology* 2008;379:284–93. [PubMed: 18692214]
91. Hijazi N, Kariv-Inbal Z, Gasset M, Gabizon R. PrP^{Sc} incorporation to cells requires endogenous glycosaminoglycan expression. *J Biol Chem* 2005;280:17057–61. [PubMed: 15668233]
92. Paquet S, Daude N, Courageot MP, Chapuis J, Laude H, Vilette D. PrP^c does not mediate internalization of PrP^{Sc} but is required at an early stage for de novo prion infection of Rov cells. *J Virol* 2007;81:10786–91. [PubMed: 17626095]
93. Gauczynski S, Nikles D, El-Gogo S, Papy-Garcia D, Rey C, et al. The 37-kDa/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfated glycanes. *J Infect Dis* 2006;194:702–9. [PubMed: 16897671]
94. Jeffrey M, Martin S, Gonzalez L. Cell-associated variants of disease-specific prion protein immunolabelling are found in different sources of sheep transmissible spongiform encephalopathy. *J Gen Virol* 2003;84:1033–45. [PubMed: 12655107]
95. Baron GS, Magalhaes AC, Prado MA, Caughey B. Mouse-adapted scrapie infection of SN56 cells: greater efficiency with microsome-associated versus purified PrP-res. *J Virol* 2006;80:2106–17. [PubMed: 16474119]
96. Baron GS, Caughey B. Effect of glycosylphosphatidylinositol anchor-dependent and - independent prion protein association with model raft membranes on conversion to the protease-resistant Isoform. *J Biol Chem* 2003;278:14883–92. [PubMed: 12594216]
97. Baron GS, Wehrly K, Dorward DW, Chesebro B, Caughey B. Conversion of raft associated prion protein to the protease-resistant state requires insertion of PrP-res (PrP(Sc)) into contiguous membranes. *EMBO J* 2002;21:1031–40. [PubMed: 11867531]

98. Flechsig E, Hegyi I, Enari M, Schwarz P, Collinge J, Weissmann C. Transmission of scrapie by steel-surface-bound prions. *Mol Med* 2001;7:679–84. [PubMed: 11713367]
99. Paquet S, Langevin C, Chapuis J, Jackson GS, Laude H, Vilette D. Efficient dissemination of prions through preferential transmission to nearby cells. *J Gen Virol* 2007;88:706–13. [PubMed: 17251590]
100. Fevrier B, Vilette D, Archer F, Loew D, Faigle W, et al. Cells release prions in association with exosomes. *Proc Natl Acad Sci U S A* 2004;101:9683–8. [PubMed: 15210972]
101. Vella LJ, Sharples RA, Lawson VA, Masters CL, Cappai R, Hill AF. Packaging of prions into exosomes is associated with a novel pathway of PrP processing. *J Pathol* 2007;211:582–90. [PubMed: 17334982]
102. McGovern G, Jeffrey M. Scrapie-specific pathology of sheep lymphoid tissues. *PLoS ONE* 2007;2:e1304. [PubMed: 18074028]
103. Rustom A, Saffrich R, Markovic I, Walther P, Gerdes HH. Nanotubular highways for intercellular organelle transport. *Science* 2004;303:1007–10. [PubMed: 14963329]
104. Caughey B, Baron GS. Prions and their partners in crime. *Nature* 2006;443:803–10. [PubMed: 17051207]
105. Gerdes HH, Carvalho RN. Intercellular transfer mediated by tunneling nanotubes. *Curr Opin Cell Biol* 2008;20:470–5. [PubMed: 18456488]
106. Leblanc P, Alais S, Porto-Carreiro I, Lehmann S, Grassi J, et al. Retrovirus infection strongly enhances scrapie infectivity release in cell culture. *EMBO J* 2006;25:2674–85. [PubMed: 16724107]
107. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. *Annu Rev Neurosci* 2003;26:267–98. [PubMed: 12704221]
108. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. *J Neurochem* 2007;101:1172–84. [PubMed: 17286590]
109. Jeffrey M, Goodsir CM, Bruce ME, McBride PA, Farquhar C. Morphogenesis of amyloid plaques in 87V murine scrapie. *Neuropath Appl Neurobiol* 1994;20:535–42.
110. Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, et al. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. *J Neurosci* 2008;28:4283–92. [PubMed: 18417708]
111. Belichenko PV, Brown D, Jeffrey M, Fraser JR. Dendritic and synaptic alterations of hippocampal pyramidal neurones in scrapie-infected mice. *Neuropathol Appl Neurobiol* 2000;26:143–9. [PubMed: 10840277]
112. Jeffrey M, Goodsir CM, Race RE, Chesebro B. Scrapie-specific neuronal lesions are independent of neuronal PrP expression. *Ann Neurol* 2004;55:781–92. [PubMed: 15174012]
113. Liberski P. Tht tubulovesicular structures-the ultrastructural hallmark for all prion diseases. *Acta Neurobiol Exp* 2008;68:113–21.
114. Eberl H, Tittmann P, Glockshuber R. Characterization of recombinant, membrane-attached full-length prion protein. *J Biol Chem* 2004;279:25058–65. [PubMed: 15031284]
115. Hicks MR, Gill AC, Bath IK, Rullay AK, Sylvester ID, et al. Synthesis and structural characterization of a mimetic membrane-anchored prion protein. *FEBS J* 2006;273:1285–99. [PubMed: 16519692]
116. Elfrink K, Ollesch J, Stohr J, Willbold D, Riesner D, Gerwert K. Structural changes of membrane-anchored native PrP(C). *Proc Natl Acad Sci U S A* 2008;105:10815–9. [PubMed: 18669653]
117. Morillas M, Swietnicki W, Gambetti P, Surewicz WK. Membrane environment alters the conformational structure of the recombinant human prion protein. *J Biol Chem* 1999;274:36859–65. [PubMed: 10601237]
118. Bahadi R, Farrelly PV, Kenna BL, Kourie JI, Tagliavini F, et al. Channels formed with a mutant prion protein PrP(82–146) homologous to a 7-kDa fragment in diseased brain of GSS patients. *Am J Physiol Cell Physiol* 2003;285:C862–C872. [PubMed: 12814912]
119. Wang X, Wang F, Arterburn L, Wollmann R, Ma J. The interaction between cytoplasmic prion protein and the hydrophobic lipid core of membrane correlates with neurotoxicity. *J Biol Chem* 2006;281:13559–65. [PubMed: 16537534]

120. Wang F, Yang F, Hu Y, Wang X, Wang X, et al. Lipid interaction converts prion protein to a PrP^{Sc}-like proteinase K-resistant conformation under physiological conditions. *Biochemistry* 2007;46:7045–53. [PubMed: 17503780]
121. Kazlauskaitė J, Sanghera N, Sylvester I, Venien-Bryan C, Pinheiro TJ. Structural changes of the prion protein in lipid membranes leading to aggregation and fibrillization. *Biochemistry* 2003;42:3295–304. [PubMed: 12641461]
122. Sanghera N, Pinheiro TJ. Binding of prion protein to lipid membranes and implications for prion conversion. *J Mol Biol* 2002;315:1241–56. [PubMed: 11827491]
123. Simoneau S, Rezaei H, Sales N, Kaiser-Schulz G, Lefebvre-Roque M, et al. In vitro and in vivo neurotoxicity of prion protein oligomers. *PLoS Pathog* 2007;3:e125. [PubMed: 17784787]
124. Stahl N, Baldwin MA, Burlingame AL, Prusiner SB. Identification of glycoinositol phospholipid linked and truncated forms of the scrapie prion protein. *Biochemistry* 1990;29:8879–84. [PubMed: 1980209]
125. Caughey B. Interactions between prion protein isoforms: the kiss of death? *Trends Biochem Sci* 2001;26:235–42. [PubMed: 11295556]
126. Wegmann S, Miesbauer M, Winklhofer KF, Tatzelt J, Muller DJ. Observing fibrillar assemblies on scrapie-infected cells. *Pflugers Arch* 2008;456:83–93. [PubMed: 18175144]
127. Bueler H, Fischer M, Lang Y, Bluethmann H, Lipp H-P, et al. Normal development and behavior of mice lacking the neuronal cell-surface PrP protein. *Nature* 1992;356:577–82. [PubMed: 1373228]
128. Mallucci GR, Ratte S, Asante EA, Linehan J, Gowland I, et al. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. *EMBO J* 2002;21:202–10. [PubMed: 11823413]
129. Li A, Piccardo P, Barmada SJ, Ghetti B, Harris DA. Prion protein with an octapeptide insertion has impaired neuroprotective activity in transgenic mice. *EMBO J* 2007;26:2777–85. [PubMed: 17510630]
130. Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A, et al. Normal host prion protein necessary for scrapie-induced neurotoxicity. *Nature* 1996;379:339–43. [PubMed: 8552188]
131. Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, Collinge J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. *Science* 2003;302:871–4. [PubMed: 14593181]
132. Race R, Oldstone M, Chesebro B. Entry versus blockade of brain infection following oral or intraperitoneal scrapie administration: Role of prion protein expression in peripheral nerves and spleen. *J Virol* 2000;74:828–33. [PubMed: 10623745]
133. Raeber AJ, Race RE, Brandner S, Priola SA, Sailer A, et al. Astrocyte-specific expression of hamster prion protein (PrP) renders PrP knockout mice susceptible to hamster scrapie. *EMBO J* 1997;16:6057–65. [PubMed: 9321385]
134. Marella M, Gaggioli C, Batoz M, Deckert M, Tartare-Deckert S, Chabry J. Pathological prion protein exposure switches on neuronal mitogen-activated protein kinase pathway resulting in microglia recruitment. *J Biol Chem* 2005;280:1529–34. [PubMed: 15528202]
135. Giese A, Brown DR, Groschup MH, Feldmann C, Haist I, Kretzschmar HA. Role of microglia in neuronal cell death in prion disease. *Brain Pathol* 1998;8:449–57. [PubMed: 9669696]
136. Harris DA, True HL. New insights into prion structure and toxicity. *Neuron* 2006;50:353–7. [PubMed: 16675391]
137. Linden R, Martins VR, Prado MA, Cammarota M, Izquierdo I, Brentani RR. Physiology of the prion protein. *Physiol Rev* 2008;88:673–728. [PubMed: 18391177]
138. Solforosi L, Criado JR, McGavern DB, Wirz S, Sanchez-Alavez M, et al. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. *Science* 2004;303:1514–6. [PubMed: 14752167]
139. Watts JC, Westaway D. The prion protein family: diversity, rivalry, and dysfunction. *Biochim Biophys Acta* 2007;1772:654–72. [PubMed: 17562432]
140. Kristiansen M, Deriziotis P, Dimcheff DE, Jackson GS, Ovaa H, et al. Disease-associated prion protein oligomers inhibit the 26S proteasome. *Mol Cell* 2007;26:175–88. [PubMed: 17466621]
141. Fowler DM, Koulov AV, Balch WE, Kelly JW. Functional amyloid—from bacteria to humans. *Trends Biochem Sci* 2007;32:217–24. [PubMed: 17412596]

142. Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. *Annu Rev Biochem* 2006;75:333–66. [PubMed: 16756495]
143. Wickner RB, Edskes HK, Shewmaker F, Nakayashiki T. Prions of fungi: inherited structures and biological roles. *Nat Rev Microbiol* 2007;5:611–8. [PubMed: 17632572]
144. Derkatch IL, Bradley ME, Hong JY, Liebman SW. Prions affect the appearance of other prions: the story of [PIN(+)]. *Cell* 2001;106:171–82. [PubMed: 11511345]
145. Coustou-Linares V, Maddelein ML, Begueret J, Saupe SJ. In vivo aggregation of the HET-s prion protein of the fungus *Podospora anserina*. *Mol Microbiol* 2001;42:1325–35. [PubMed: 11886562]
146. Kicka S, Bonnet C, Sobering AK, Ganesan LP, Silar P. A mitotically inheritable unit containing a MAP kinase module. *Proc Natl Acad Sci U S A* 2006;103:13445–50. [PubMed: 16938837]
147. Kisilevsky R. Preparation and propagation of amyloid-enhancing factor. *Methods Mol Biol* 2005;299:237–41. [PubMed: 15980607]
148. Lundmark K, Westermark GT, Nystrom S, Murphy CL, Solomon A, Westermark P. Transmissibility of systemic amyloidosis by a prion-like mechanism. *Proc Natl Acad Sci U S A* 2002;99:6979–84. [PubMed: 12011456]
149. Papendick RE, Munson L, O'Brien TD, Johnson KH. Systemic AA amyloidosis in captive cheetahs (*Acinonyx jubatus*). *Vet Pathol* 1997;34:549–56. [PubMed: 9396135]
150. Munson L, Terio KA, Worley M, Jago M, Bagot-Smith A, Marker L. Extrinsic factors significantly affect patterns of disease in free-ranging and captive cheetah (*Acinonyx jubatus*) populations. *J Wildl Dis* 2005;41:542–8. [PubMed: 16244064]
151. Zhang B, Une Y, Fu X, Yan J, Ge F, et al. Fecal transmission of AA amyloidosis in the cheetah contributes to high incidence of disease. *Proc Natl Acad Sci USA*. 2008
152. Xing Y, Nakamura A, Chiba T, Kogishi K, Matsushita T, et al. Transmission of mouse senile amyloidosis. *Lab Invest* 2001;81:493–9. [PubMed: 11304568]
153. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. *Science* 2006;313:1781–4. [PubMed: 16990547]
154. Si K, Lindquist S, Kandel ER. A neuronal isoform of the aplysia CPEB has prion-like properties. *Cell* 2003;115:879–91. [PubMed: 14697205]
155. Walker LC, LeVine H III, Mattson MP, Jucker M. Inducible proteopathies. *Trends Neurosci* 2006;29:438–43. [PubMed: 16806508]
156. Lee KS, Caughey B. A simplified recipe for prions. *Proc Natl Acad Sci U S A* 2007;104:9551–2. [PubMed: 17535888]
157. Ma J, Wollmann R, Lindquist S. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. *Science* 2002;298:1781–5. [PubMed: 12386337]
158. Kristiansen M, Messenger MJ, Klohn PC, Brandner S, Wadsworth JD, et al. Disease-related prion protein forms aggregates in neuronal cells leading to caspase activation and apoptosis. *J Biol Chem* 2005;280:38851–61. [PubMed: 16157591]

A seeded polymerization (autocatalytic or templated)



B seeded polymerization (noncatalytic)




Figure 1. Seeded PrP polymerization mechanisms. In the non-catalytic model, the conformational interchange between the PrP^{C} and PrP^{RES} conformations is rapid, but the PrP^{RES} conformer is poorly populated unless stabilized by binding to an existing PrP^{RES} multimer. In the autocatalytic model, the conformational conversion of PrP^{C} to PrP^{RES} is rare unless catalyzed by contact with an existing PrP^{RES} multimer.




Figure 2. Models of TSE prion amplification by PMCA. A. PMCA flow chart based on (3,4). B. Seeded polymerization model for PrP^{RES} formation with the aid of a polyanion (e.g. polyA RNA) (4). Adapted from (156).




Figure 3. Ultrastructures and models of PrP^{RES} fibrils. A. Negative-stained transmission electron micrographs of proteinase K-treated wild-type or GPI-anchorless PrP^{RES} amyloid fibrils (34). B. Electron micrographs and crystallographically refined images of hexagonal 2D crystals and of proteinase K-treated PrP^{RES}. On the left, the 2D crystals are shown together with fibrils. Adapted from (45). C. Top-down view of PrP^{RES} trimers according to the spiral (47,48) and β -helix (46) models. Glycans (aqua), α -helices (blue) and β -strands (green) are highlighted. Adapted from (48). D. Parallel, in-register β -sheet model of synthetic fibrils of human PrP residues 120-231. Adapted from (50).




Figure 4.

Model of biogenesis and accumulation of PrP^{RES} in scrapie-infected cells. As a GPI-anchored plasma membrane glycoprotein (upper right), PrP^C is first synthesized in the endoplasmic reticulum (ER), processed in the Golgi apparatus, and transported to the cell surface (bottom). PrP^{RES}, together with apparent cofactors, directly induces the conversion of GPI-anchored PrP^C on the cell surface and/or in endosomes. PrP^C that is released from the cell may be converted on extracellular deposits such as amyloid fibrils. Once PrP^{RES} is made, it can accumulate on the cell surface, in intracellular vesicles (e.g. lysosomes) and aggresomes, or in extracellular deposits. Under conditions of mild proteasome inhibition, cytotoxic cytoplasmic PrP aggregates (e.g., aggresomes) can be found (157,158). Scrapie infection alone can inhibit proteasomes, apparently due to the presence of cytoplasmic PrP oligomers (140).




Figure 5. Different patterns of PrP^{RES} deposition in brain tissue of scrapie-infected mice expressing wildtype (top) versus anchorless PrP^C (bottom) (29). The sections shown are from the hippocampus in the vicinity of the dentate gyrus. The photos are courtesy of Dr. Bruce Chesebro, Rocky Mountain Laboratories.




Figure 6. Neuritic transport of PrP^{RES} during acute infection. SN56 mouse neuroblastoma cells were treated with Alexa Fluor 568-labeled mouse PrP^{RES} and imaged at 4 d post-infection. Arrows (left panel) indicate examples of fluorescent PrP^{RES} particles transported within neuritic processes that contact other neurites and cells (89). Left panel shows Alexa Fluor 568 fluorescence. Right panel shows Alexa Fluor 568 fluorescence superimposed on a differential interference contrast image.




Figure 7.

Potential mechanisms of intercellular spread of prions. A) Exosomes/membrane microparticles. Prion-infected cells release PrP^{RES}-containing membrane vesicles that deliver PrP^{RES} (red squares) to membranes of uninfected cells to initiate new PrP^{RES} formation (blue squares) in recipient cells (95–97). These include exosomes, vesicles generated by invagination of the limiting membranes of multivesicular bodies (MVBs) and released by MVB fusion with the plasma membrane (100). Delivery of membrane vesicles could occur at the cell surface (not shown) or in an endocytic compartment. B) Tunneling nanotubes (TNTs). TNTs are visualized as thin intercellular projections (Top view, Merged, arrow) through space (see Side view, Merged) in a co-culture of two cell lines expressing either a GPI-anchored protein tagged with GFP (green) or one tagged with mCherry (magenta) fluorescent protein. The arrowhead (Top view, Merged, white area) shows a TNT that has facilitated the transfer of GFP-tagged protein onto the surface of the mCherry-expressing cell. Side view (Merged) corresponds to a side view of a 3D volume rendering of the area indicated by the dotted rectangle in Top view (Merged). DIC, differential interference contrast image.




Figure 8. Abnormal PrP (PrP^d) accumulation and membrane distortions on the surface of neurons and astrocytes in scrapie-infected sheep brain tissue. PrP^d is labeled with immunogold particles. A. PrP^d on the plasma membrane of a neuron without morphological changes. B. Complex dendrite membrane disturbances (microfolding-asterisks) associated with the formation of abnormal pits (not immunolabeled). C. PrP^d accumulation associated with the formation of excess coated pits (arrows) and with the transfer to membranes of adjacent processes (arrow heads). D. coated membrane invaginations, one of which shows a spiral, twisted neck (not immunolabeled). E. PrP^d on the plasma membrane of astrocytic processes containing abundant glial filaments. Parts of the plasmalemma of some processes have linear segments (arrowheads) suggesting increased membrane rigidity and incipient fibril formation. Adapted from (78).